Plain Language Summary of the Manuscript: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

W. le Roux, Carel; steen, Oren; J Lucas, Kathryn; Startseva, Elena; Unseld, Anna; M. Hennige, Anita

doi:10.60915/Boehringer-figshare.27720057.v4

Plain Language Summary of the Manuscript: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

journal contribution

posted on 2024-11-25, 10:47 authored by Carel W. le Roux, Oren steen, Kathryn J Lucas, Elena Startseva, Anna Unseld, Anita M. Hennige

The above is a plain language summary of a publication developed with the authors of the original content which is published in a peer-reviewed scientific journal/presented in a conference.

Funding

This study was sponsored by Boehringer Ingelheim

History

Disclaimer

The PLS content is not peer-reviewed. Unless otherwise specified, the content on this website has undergone a medical, legal, and regulatory (MLR) review and medical scientific accuracy review by Boehringer Ingelheim. The publisher of the original manuscript was not involved in the preparation of this PLS and has neither reviewed nor approved its content.

Plain Language Summary of the Manuscript: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

Funding

This study was sponsored by Boehringer Ingelheim

History

Disclaimer

More information

Usage metrics

Categories

Keywords

Licence

Exports